Drug Trial Radar · NCT01467713
Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder
Last checked: Nov 20, 2026Latest source record: May 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
642
Actual
Start
Dec 2011
Primary completion
Mar 2015
Study completion Mar 2015
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Nov 9, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of ramelteon, once nightly before bedtime (QHS), sublingual (SL), in the maintenance treatment of Bipolar I Disorder in adult patients.
Conditions
- Bipolar Disorder
Interventions
Ramelteon SLDrug
Ramelteon sublingual (SL) tablets
PlaceboDrug
Ramelteon sublingual (SL) placebo-matching tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time From Randomization to Any RelapseTime frame: Randomization to Month 12 double-blind treatment period
Locations
156 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Dothan, Alabama
Site not named
Muscle Shoals, Alabama
Site not named
Phoenix, Arizona
Site not named
Little Rock, Arkansas
Site not named
Bellflower, California
Site not named
Costa Mesa, California
Site not named
Garden Grove, California
Site not named
Harbor City, California
Site not named
Huntington Park, California
Site not named
Irvine, California
Site not named
Lomita, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Murrieta, California
Site not named
National City, California
Site not named
Oceanside, California
Site not named
Orange, California
Site not named
Paramount, California
Site not named
Rancho Cucamonga, California
Site not named
Redondo Beach, California
Site not named
Riverside, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Jose, California
Site not named
San Ramon, California
Site not named
Sherman Oaks, California
Site not named
Torrance, California
Site not named
Wildomar, California
Site not named
Colorado Springs, Colorado
Site not named
Denver, Colorado
Site not named
Norwalk, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Clearwater, Florida
Site not named
Coral Gables, Florida
Site not named
Coral Springs, Florida
Site not named
Edgewater, Florida
Site not named
Hialeah, Florida
Site not named
Jacksonville, Florida
Site not named
Leesburg, Florida
Showing 40 of 156 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.